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Recent development of a wide range of regulatory standards applicable to production and use of
tissues, cells, and other biologics (or biologicals), as advanced therapies, indicates considerable
interest in the regulation of these products. The objective of this study was to analyze and compare
high-tier documents within the Australian, European, and U.S. biologic drug regulatory environ-
ments using qualitative methodology. Cohort 1 of the selected 18 high-tier regulatory documents
from the EuropeanMedicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the
Therapeutic Goods Administration (TGA) regulatory frameworks were subject to a manual docu-
mentary analysis. These documents were consistent with the legal requirements for manufacturing
and use of biologic drugs in humans and fall into six different categories. Manual analysis included a
terminology search. The occurrence, frequency, and interchangeable use of different terms and
phrases were recorded in the manual documentary analysis. Despite obvious differences, manual
documentary analysis revealed certain consistency in use of terminology across analyzed frame-
works. Phrase search frequencies have shown less uniformity than the search of terms. Overall, the
EMA framework’s documents referred to “medicinal products” and “marketing authorization(s),”
the FDA documents discussed “drug(s)” or “biologic(s),” and the TGA documents referred to “bio-
logical(s).” Although high-tier documents often use different terminology they share concepts and
themes. Documents originating from the same source have more conjunction in their terminology
although theybelong todifferent frameworks (i.e., GoodClinical Practice requirements basedon the
Declaration of Helsinki, 1964). Automated (software-based) documentary analysis should be ob-
tained for the conceptual and relational analysis. STEM CELLS TRANSLATIONAL MEDICINE
2012;1:898–908
INTRODUCTION
Recent development of a wide range of regula-
tory standards applicable to production and use
of tissues, cells, and other biologics (or biologi-
cals)—as advanced therapies—has stimulated
considerable interest in the regulation of biologic
drugs (including but not limited to human cell
and tissue therapies) as part of the vast array of
biopharmaceuticals. Biologic drug regulations
have been widely developed by mature regula-
tory agencies; for example, the Australian frame-
work is administered by the Therapeutic Goods
Administration (TGA), the European Union’s by
the EuropeanMedicines Agency (EMA), and that
of the U.S. by the Food and Drug Administration
(FDA) [1].
A significant number of documents are cur-
rently available in the analyzed regulatory frame-
works (supplemental online data 1) in the form
of standards, guidelines, recommendations, or
regulations [2]. Conditions of product manufac-
turing and release have been established and
outlined in a spectrum of documents from the
high-tier regulatory documents down to proce-
dural documents. However, one of the major is-
sues facing manufacturers, clinical practitioners,
patients, patient advocacy groups, investors, and
the general public is confusion over terminology
at various levels and in types of documents appli-
cable to specific products (i.e., stem cells vs. so-
matic cells vs. biologics vs. biologicals) [2–6]. Ad-
ditional misperceptions can be attributed to the
unclear level of regulatory oversight required,
different levels of scrutiny (i.e., control of an en-
tire manufacturing facility vs. control of a manu-
facturing process), differences in availability of
specific formal written procedures (i.e., some reg-
ulatory documents are deemed overly prescriptive
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or overly generic), and different product testing and release re-
quirements [2–6]. Nonetheless, complex regulations are meant
to be adhered to at all times and in every aspect of the manufac-
turing of biologic drugs (including but not limited to human cell
and tissue therapies).
For the purpose of this paper all the products mentioned
abovewill be referred to as biologic drugs, although other termi-
nology may be used in the literature [3]; additionally, a consen-
sus has not been reached entirely on the use of the term “drug”
[4], the regulatory oversight required [5], and established indus-
try models [6]. An extensive overview of regulatory documents
(available on websites) and the list of abbreviations and addi-
tional definitions used in this study are presented in supplemen-
tal online data 1 and supplemental online data 2, respectively.
The intention of the research is to compare the content and
terminology in high-tier regulatory documents related to bio-
logic drugs in Australia, Europe, and the U.S., where these prod-
ucts are also referred to as biologicals, advanced therapy medic-
inal products, and biologics, respectively. Since stem cells are
“biologics,” these regulations are of major importance to all
those attempting to translate stem cells into clinical trials and
clinical practice.
Definitions
The TGA regulatory documents refer to biological as follows:
Essentially a biological comprises, contains or is derived
from human cells or human tissues . . . and is used to:
treat or prevent disease, ailment, defect or injury; or diag-
nose the condition of a person; or influence, inhibit or
modify a physiological process in persons; or test the sus-
ceptibility of persons to a disease or ailment; or replace or
modify parts of the anatomy in persons [7].
The official FDA definition of biological products or biologics
can be summarized as “any virus, therapeutic serum, toxin, anti-
toxin or analogous product applicable to the prevention, treat-
ment or cure of diseases or injuries of man,” whereas the FDA
Consumer Information page states:
Biological products include a wide range of products such
as vaccines, blood and blood components, allergenics, so-
matic cells, gene therapy, tissues, and recombinant ther-
apeutic proteins. Biologics can be composed of sugars,
proteins, or nucleic acids or complex combinations of
these substances, or may be living entities such as cells
and tissues. Biologics are isolated from a variety of natural
sources—human, animal, ormicroorganism—andmay be
produced by biotechnology methods and other cutting-
edge technologies. Gene-based and cellular biologics, for
example, often are at the forefront of biomedical re-
search, andmay be used to treat a variety of medical con-
ditions for which no other treatments are available [8].
The lengthy official definition (codified in 21 CFR 600.3) vaguely
defines biologics on the basis of analogies (i.e., products similar
to viruses, serums, toxins, and antitoxins) [9]. This definition
avoids terms and concepts in use for generations (i.e., proteins,
antibodies, genes, microbes, cells, viruses, and DNA/RNA). In
practice, biologics include “a wide range of products such as vac-
cines, blood and blood components, allergenics, somatic cells,
gene therapy, tissues and recombinant therapeutic proteins” [9].
The European Parliament Regulation 1394/2007 (amending
directive 2001/83/EC and Regulation 726/2004) identifies an ad-
vanced therapy medicinal product (ATMP) as
a medicinal product as defined in Directive 2001/83/EC of
the European Parliament and of the Council of 6 Novem-
ber 2001 on the Community code relating to medicinal
products for human use (the Directive), as amended to
reflect new innovative therapeutic products. Specifically,
an ATMP is a biological medicinal product which is either:
• a gene therapy medicinal product as defined in Part IV
of Annex I to Directive 2001/83/EC;
• a somatic cell therapy medicinal product as defined in
Part IV of Annex I to Directive 2001/83/EC; or
• a tissue engineered product as defined in Article 21(b)
of the ATMP Regulation (1394/2007/EC) [10].
Aim, Purpose, and Scope
The purpose of this study is to provide a comparison of regula-
tory documents pertinent to biologic drugs in different regula-
tory frameworks. To accomplish this, an assessment of particular
documents was obtained. The scope of the study included regu-
lations of biologic drugs in Australia, Europe, and the U.S.; the
objective was to derive data shared between the regulatory
frameworks in order to make them usable in a harmonization
process. Exploiting the shared terminology and mutually recog-
nized scope or aim of the regulations was easiest to define via
documentary analysis of high-tier documents in each regulatory
scheme. It was hypothesized that there are similarities between
high-tier regulatory documents related to biologic drugs in Aus-
tralia, Europe, and the U.S., although the terminology and focus
of these regulatory frameworks differ to some extent. It was also
anticipated that high-tier regulatory documents could be taken
as a central representation of the regulatory frameworks from
which they were drawn. The overall aim of the study was to
establish a correlation between a manual analysis (Part I) and a
software analysis (Part II) [11], to assess usability of the software
analysis, and to ascertain the use of a qualitativemethodology in
the highly specialized area of regulatory science.
Complexity
Taking newly created biomedical discoveries from the bench to
the bedside has proven to be a highly challenging and costly
exercise [12]. It has been defined as translational research and
recognized by researchers and funding agencies and more re-
cently by regulatory agencies as an imminent need [12]. Success
in translational research requires not only highly trained experts
and complex skill sets within a teambut also an understanding of
the application of data in different regulatory sets of principles
[13]. Independent development of regulatory authorities in Aus-
tralia, Europe, and the U.S. has led to differences in the regional
approach to pharmaceutical manufacturing. Some of thesewere
favorable for the conduct of early clinical trials withminimal sup-
porting data. Others have been affected by external factors (e.g.,
cultural) or have expanded their scope through the years. Recent
efforts have been made to harmonize the three frameworks,
mostly in the area of active pharmaceutical ingredient inspec-
tions [14], and are expected to be followed by other joint
programs.
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Although therapeutics derived from biological sources have
been subject to regulatory oversight for some time (i.e., mono-
clonal antibodies), the biologic products used in transplantation
procedures (i.e., cells and tissues) have historically been ex-
empted from such oversight [15]. The unique source of the “ac-
tive ingredients” renders cell and tissue therapies difficult for
assessment by the traditional regulatory approaches; these have
been geared to support traditional pharmaceutical manufactur-
ing practice [16]. It has been recognized that therapeutic claims
for biologics need to be supported by strong scientific evidence
[17] but also by comprehensive regulatory principles. New con-
siderations have led the existing regulatory agencies of the de-
veloped world to propound new regulatory approaches for the
sector of biologic drugs or biopharmaceuticals, which “has be-
come one of the most research-intensive sectors with a great
potential for delivering innovative human medicines in the fu-
ture” [18].
The biopharmaceutical industry is defined through a defini-
tion of biopharmaceutical products or as business activities re-
lated to the development of new biopharmaceutical drugs and
medicines [19]. Defining the term “biopharmaceutical” for the
industry’s stakeholders, including the regulatory agencies, has
proven to be a difficult task. Regulatory definitions of biophar-
maceuticals are generally based on a broad biotechnology defi-
nition but often use other terms with their own intricate
definitions (i.e., “biologicals” in Australia, “advanced therapy
medicinal products” in Europe, and “biologics” in the U.S.) [9].
Documentary analysis is a usefulmethodology to clarify the com-
plexity of biologic drug regulations, as part of the complex regu-
latory arena of biopharmaceuticals [20].
Regulation of cell and tissue products is closely linked not
only to sensitive areas of public health policy and funding but
also to the development of novel disciplines such as regulatory
science [19, 21]. This positions regulators in a challenging posi-
tion as they attempt to reconcile their roles as independent as-
sessors with public health needs and perceptions [19, 21]. The
historical background—in the development of regulatory agen-
cies of interest—has been explored previously [22], and the re-
gional differences were illustrated by observations pertinent to
their clinical trial requirements [23–29]. These differences inev-
itably contribute to the complexity of the regulations applicable
to the development of biologic drugs.
MATERIALS AND METHODS
Materials
Documents and written material used in this research provided a
way of gaining access to sets of processes that cannot be observed
or documented otherwise and are not easily described in verbal or
other reconstructions [20].Documentsused in this studywereread-
ily available onwebsites because of their purpose. They were com-
plete, well constructed, and clearly presented.
The main tasks in the analysis were (a) the selection process
of documents to be analyzed, due to the vastness of thematerial
available, and (b) the thorough reading and analysis of selected
documents. The type of sampling used in this research was the-
oretical or purposive sampling for high-tier regulatory docu-
ments that are, for purposes of this research, taken as the central
representation of the regulatory frameworks from which they
were drawn. The sampling approach is outlined in Table 1, indi-
cating the inclusion and exclusion criteria. An extensive list of
analyzed documents is presented in Table 2.
Methods
Manual analysis of selected documents identified main terms
and phrases in individual documents. While undertaking data
analysis, important consideration was given to selectivity and
the perspective of the research, that is, how to maintain focus
in the process of documentary analysis. This was related to
the question of what the documents were expected to pro-
vide in an ontological and epistemological sense. The process
of analysis involved several steps. First, the context was es-
tablished and the complexity and historical background were
explored for each of the analyzed sets of regulatory principles.
Second, extensive preparation for analysis and selection of
documents was obtained. Finally, selected documents were
copied from the official regulatory agencies’ websites and ex-
amined. Since the interest of the research was predominantly
Table 1. Inclusion and exclusion criteria for selection of documents
Parameters Inclusion criteria Exclusion criteria
Location E.U., U.S., and Australia Regions other than the E.U., U.S., and Australia
Language English Documents not written in English




Legal requirements for manufacture and use of biologic
drugs for human use, including definitions and scope
GMP for manufacture of medicinal products and
biologic drugs for human use
GCP for use of medicinal products and biologic drugs in
clinical trials involving humans
Documents concerned with issues other than
legal requirements for manufacture, GMP,
and GCP applicable to medicinal products
and biologic drugs for human use
Scope of the
document
Medicinal products, biologics, biologicals, and ATMPs
for human use
Documents concerned with other than
medicinal products, biologics, biologicals,
and ATMPs for human use
Time frame Most recent documents published from 2000
(inclusive)
Documents published prior to 2000a
aOnly one document was exempt, as it was originally published in 1996 (see Table 4).
Abbreviations: ATMP, advanced therapy medicinal products; E.U., European Union; GCP, Good Clinical Practice; GMP, Good Manufacturing
Practice.
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in the literal wording and terminology, as a demonstration of
the documents’ focus and intent, a manual method (Table 3)
was devised to record these.
An overviewof the newTGAwebsite structure and content is
presented in supplemental online data 1a. It includes only the
new Biologicals Framework established in July 2011 [26–29].
Relevant documents were selected from the newly established
TGA regulations [26–29]. In terms of the European Union (E.U.)
regulatory requirements, selection of the documents was not
straightforward due to the complexity of national and EMA reg-
ulations (presented in supplemental online data 1b). It is ac-
knowledged by the EMA that new technologies, therapies, and
medicines are emerging in the form of regenerative medicine
and more personalized treatments [23, 24]. The lack of an E.U.-
wide regulatory framework in the past led to divergent national
approaches that hindered patient access to products, and as a
Table 2. List of analyzed documents










EMA DOC1 Directive 2001/83/EC n/a 2001 Yesa
EMA DOC2 Regulation 726/2004 n/a 2004 Yesa
EMA DOC3 Regulation 1394/2007 n/a 2007 Yes
FDAb
Document code
FDA DOC1 21CFR312 n/a 2011 Yes
FDA DOC2 21CFR600 Biological Products: General n/a 2011 Yes
FDA DOC3 21CFR1271 Human Cells, Tissues, and Cellular and Tissue-Based Products n/a 2011 Yes
TGA
Document code
TGA DOC1 Australian Regulatory Guidelines for Biologicals Part 1 1.0 2011 Yes
TGA DOC2 Australian Regulatory Guidelines for Biologicals Part 2 1.0 2011 Yes





GMP DOC1 Directive 2003/94/EC (EMA) n/a 2003 Yes
GMP DOC2 Australian Code of Good Manufacturing Practice—Human Blood and Tissues (TGA) n/a 2000 Yesc




GMP DOC4 21CFR211 Current Good Manufacturing Practice for Finished Pharmaceuticals n/a 2011 Yes
GMP DOC5 Guide to Good Manufacturing Practice for medicinal Products—Part I (PIC/S) n/a 2009 Yes
GMP DOC6 Guide to Good Manufacturing Practice for medicinal Products—Part II (PIC/S) n/a 2009 Yes
Good Clinical Practice
Document code
GCP DOC1 Directive 2003/20/EC (EMA) n/a 2001 Yes
GCP DOC2 Guidance for Industry E6 Good Clinical Practice (FDA) n/a 1996d Yes
GCP DOC3 Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) Annotated (TGA) n/a 2000 Yes
aSubsequently amended.
bDisclaimer: Major, specific, and updated FDA guidances relating to key subsets of biologics were not included in cohort 1 and 2 documents.
Although the basic FDA regulations have not been changed much since the expansion of biologic drugs, including vaccines, the guidances have
really become more like regulations in the interim. Due to the research sampling criteria, guidances (including the key manufacturing guidances for
biologics that the FDA really does enforce in a way similar to that for regulations) have not been analyzed here. These documents can be found at
the following link: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm.
cIn the process of being amended.
dDocument was exempt from the time frame.
Abbreviations: DOC, document; EMA, European Medicines Agency; FDA, Food and Drug Administration; GCP, Good Clinical Practice; GMP, Good
Manufacturing Practice; n/a, not applicable; PIC/S, Pharmaceutical Inspection Convention/Cooperation Scheme; TGA, Therapeutic Goods
Administration.
Table 3. Literal wording, form, and sequence manual recording in the documents
Manual document analysis Considerations Question raised Stage result
Stage 1: Selection of documents (including
comparison with other frameworks/areas)
• Regulatory frameworks (by region)
• Areas of regulatory frameworks
What to analyze • List of documents to be analyzed
Stage 2: Reading and “interpretation” • Purpose and aim of documents
• Understanding of the content
How to analyze • Thorough understanding of aim,
scope and depth of documents
• List of terms and phrases to search
Stage 3: Search by key word and/or by phrase • Generalizability of terms




• Frequencies of specific
terminology and/or phrases
Stage 4: Recording and reconciliation of findings
(including tabulation of results)
• Consistency and quality assurance
• Presenting results in an adequate
manner
Reliability of results • Tables and diagrams outlining
results of the manual analysis
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result the central procedure was established [23, 24]. As a fur-
ther illustration of the complexity and vastness of written mate-
rial available in the area of biologic drug regulations, an overview
of the relevant FDA regulations since 2004 [30–34] is briefly pre-
sented in supplemental online data 1c. Some of these docu-
ments were selected for the analysis, based on the inclusion and
exclusion criteria, and a provision was made in relation to so
called “nonbinding” documents in the formof guidances (see the
Disclaimer in Table 2). In terms of sampling, it was essential to
decide what was significant in the context of the research, its
theoretical and empirical referents, and how it related to the
broader universe [35–37].
RESULTS
Data presented in Tables 4 and 5 were derived from the manual
analysis, using the PDF search feature to assess the documents in
cohort 1 (see Table 2). Rather than treating the data as an end
product (i.e., variable), it was classified and subsequently parts
or “slices” were treated as unfinished resources for further use
[20]. Manual analysis included a terminology search with a list of
10 specific terms (Table 4) and 16 phrases (Table 5). The frequen-
cies of terms and phrases in the documents are also illustrated in
Figures 1 and 2.
Frequency of terms presented in Table 4 reveals certain con-
sistency across regions in the use of “manufacturing” (58, 71, and
113 occurrences in EMA, FDA, and TGA documents, respectively)
and “human” (137, 55, and 89 rates, respectively). The terms
“drug(s),” “cell(s),” and “biologic(s)/biological(s)” were to some
extent used across the entire spectrum of analyzed documents.
More frequent and specific use of “medicinal” was observed
in the EMA documents (a total of 1,092 occurrences in three
documents), whereas “pharmaceutical” was very sporadically
used in any documents other than the EMA DOC1 (54 occur-
rences). The term “therapy” or “therapies”was notmentioned in
any of the FDA documents and was seldom used in the TGA docu-
ments (13times in total),whereas itwasmentioned141times in the
EMADOC3, likely because of the definition by the EMA of cell ther-
apies as advanced therapeutic medicinal products.
Whereas the most frequent word used in the EMA docu-
ments was “product(s)” along with “medicinal,” the term
“drug(s)” was consistently mentioned within all FDA documents
(84, 34, and 36 times) but seldom mentioned in the other two
frameworks (a total of five occasions). The TGA documents fea-
tured “biologic(s)/biological(s)” most consistently, whereas
“cell(s)” was most used in a document from the FDA framework
(78 occurrences in FDA DOC3) and the TGA framework (100 oc-
currences in TGA DOC1). Considering the relevant definitions,
these search terms were expected to be dominant [23–32].
The definition of cell therapies by each of the regulatory
agencies was as follows.
Table 4. Terminology search: frequency of terms in documents (cohort 1)
Terminology search



















Approve(d)/approval(s) 16 5 0 14 9 15 24a 30 55a
Biologic/biological(s) 0 2 2 6 89 17 377 219 67
Cell(s) 1 2 46 1 5 78 100 6 1
Drug(s) 1 0 0 84 34 36 1 3 0
Human 0 84 53 11 6 38 83 1 5
Manufacturing 41 8 9 2 48 21 56 57 0
Medicinal 615 329 148 0 0 0 2 0 0
Product(s) 727 350 227 14 197 49 144 21 6
Pharmaceutical 54 8 4 1 1 0 3 0 1
Therapy(ies) 4 7 141 0 0 0 13 0 0
aIncludes term “unapproved.”
Abbreviations: DOC, document; EMA, European Medicines Agency; FDA, Food and Drug Administration; TGA, Therapeutic Goods Administration.
Table 5. Terminology search: frequency of phrases in documents (cohort 1)
Phrase search



















Access to . . . 4 7 0 5 0 1 8 0 6
Clinical investigation 0 0 0 13 1 0 0 0 0
Clinical trial 21 8 4 10 2 0 11 2 41
Class/classification of . . . 7 0 0 0 0 0 5 16 0
Human cell(s) and tissue(s) 0 0 1 0 0 1 0 0 0
Human cells 0 0 8 0 0 11 12 0 0
Investigational new drug(s) 0 0 0 16 2 0 0 0 0
Investigational drug(s) 0 0 0 14 0 0 0 0 0
Marketing authorization(s) 110 115 32 0 0 0 0 0 0
Marketing approval(s) 0 0 0 5 0 0 0 0 1
Medicinal product(s) 599 329 148 0 0 0 2 0 0
Product deviation(s) 0 0 0 0 11 0 0 0 0
Regulatory process 0 0 0 0 0 0 0 5 0
Quality of . . . 8 1 0 0 1 0 1 4 (7a) 0
Quality, safety, and efficacy 7 10 4 0 0 0 2 2 2
Risk(s) management 1 0 7 0 2 0 23 2 2
aFrequency of term “manufacturing quality.”
Abbreviations: DOC, document; EMA, European Medicines Agency; FDA, Food and Drug Administration; TGA, Therapeutic Goods Administration.
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● Somatic cell therapy and gene therapy-related definitions and
considerations by the FDA:
Somatic cell therapy is the administration to humans of
autologous, allogeneic, or xenogeneic living cells which
have been manipulated or processed ex vivo. Manufac-
ture of products for somatic cell therapy involves the ex
vivo propagation, expansion, selection (see: “A Proposed
Approach to the Regulation of Cellular and Tissue-based
Products,” Feb. 28, 1997, (62 FR 9721)), or pharmacologic
treatment of cells, or other alteration of their biological
characteristics. Such cellular products might also be used
for diagnostic or preventive purposes. Recently, various
innovative therapies involving the introduction of somatic
cells into humans have been used or proposed. For the
purpose of this Guidance, the term somatic cell therapy
refers to the administration to humans of autologous, al-
logeneic, or xenogeneic living non-germline cells, other
than transfusable blood products, for therapeutic, diag-
nostic, or preventive purposes. . . . Examples of somatic
cell therapies include implantation of cells as an in vivo
source of amolecular species such as an enzyme, cytokine
or coagulation factor; infusion of activated lymphoid cells
such as lymphokine activated killer cells and tumor-infil-
trating lymphocytes (addressed in a separate Points to
Consider document: see below); and implantation of ma-
nipulated cell populations, such as hepatocytes, myo-
blasts, or pancreatic islet cells, intended to perform a
complex biological function. Because of the complexities
of potential interactions with the cells and other constit-
uents, additional components should be considered as
part of the final biological product for purposes of preclin-
ical evaluation [25, 32].
● Human cell and tissue-based therapeutic goods-related defi-
nitions and considerations by the TGA:
Figure 1. Terminology search graph: frequency of terms in documents (cohort 1). Abbreviations: DOC, document; EMA, EuropeanMedicines
Agency; FDA, Food and Drug Administration; TGA, Therapeutic Goods Administration.
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The Australian Regulatory Guidelines for Biologicals
(ARGB) provide information for manufacturers, sponsors,
healthcare professionals and the general public on the
legal arrangements in Australia for the supply and use of
human cell and tissue-based therapeutic goods. These
products are collectively defined as ‘biologicals’. . . . The
Biologicals Regulatory Framework is the term for legisla-
tion that came into force in 2011 to regulate human cell
and tissue-based products as a distinct group of therapeu-
tic goods called ‘biologicals’. The framework is adminis-
tered by the Therapeutic Goods Administration (TGA),
who has produced this document—the Australian Regula-
tory Guidelines for Biologicals (ARGB)—to inform manu-
facturers, sponsors, healthcare professionals and all other
interested parties about the framework. . . . The Biologi-
cals Regulatory Framework provides a comprehensive
system of assessment and controls that must be com-
pletedbefore products are allowed tobemarketed inAus-
tralia (premarket), and follow-up and further controls af-
ter they are marketed (post-market)… or included on the
Australian Register of Therapeutic Goods (ARTG) other-
wise exempted, approved or authorised [26].
● ATMP-related definitions and considerations by the EMA:
Advanced-therapy medicinal products (ATMPs) are medi-
cines for human use that are based on gene therapy, so-
matic-cell therapy or tissue engineering. They offer
groundbreaking new opportunities for the treatment of
disease and injury. The regulatory framework for ATMPs is
established in Regulation (EC) No 1394/2007 [23].
For reasons of clarity, complex therapeutic products re-
quire precise legal definitions. Gene therapy medicinal
products and somatic cell therapy medicinal products
have been defined in Annex one to Directive 2001/83/EC,
but a legal definition of tissue engineered products re-
mains to be laid down.When products are based on viable
cells or tissues, the pharmacological, immunological or
metabolic action should be considered as the principle
mode of action. It should also be clarified that products
which do not meet the definition of a medicinal product,
such as products made exclusively of non-viablematerials
which act primarily by physical means, cannot by defini-
tion be advanced therapy medicinal products [10].
Phrase search results are shown in Table 5. The phrase “ac-
cess to” was the one most uniformly present in all documents
across the frameworks although not frequently used altogether
(a total of 31 occurrences across all frameworks’ documents).
The phrases “clinical investigation” and “clinical trial” were
interchangeably used by FDA documents, whereas EMA and TGA
documents referred only to “clinical trial.” “Human cell(s) and
tissue(s)” and “human cells” were only referred to by a single
document in each framework (9 occasions in the EMA DOC3, 12
in the FDA DOC3, and 12 in the TGA DOC1), whereas “investiga-
tional new drug” was mentioned only in two FDA documents (a
total of 32 occasions in FDA DOC1 and DOC2).
Finally, the TGA documents referred often to “manufactur-
ing” (along with other two frameworks’ documents to a lesser
extent) and “approved/unapproved,” while mentioning “cell(s)”
more than 100 times in only one of the TGA documents (TGA
DOC1). The TGA framework relied heavily on the terms “prod-
uct(s)” and “risk management” on 171 and 27 occasions, respec-
tively. “Risk management” was mentioned less frequently in the
EMA documents and only twice in all FDA documents.
The term “therapy” or “therapies” was notmentioned in any
of the FDA documents and was seldom used in the TGA docu-
ments (13 times in total), whereas it wasmentioned 141 times in
the EMA DOC3.
Overall, the EMA framework’s documents referred to “me-
dicinal products” and “marketing authorisation(s),” the FDA doc-
uments discussed “drug(s)” or “biologic(s),” and the TGA docu-
ments mentioned “biological(s).” Hence, all the documents
signified “product” as such—although they referred to it using
different terminology (“medicinal product” vs. “drug/biologic”
vs. “biological”).
Furthermore, the EMA documents were mostly concerned
with “marketing authorisation(s)” while mentioning “quality,
safety and efficacy.” In the same manner the FDA documents
discussed “drug(s)” or “investigational drug(s)” that were not
Figure 2. Terminology search graph: frequency of phrases in documents (cohort 1). Abbreviations: DOC, document; EMA, European Medi-
cines Agency; FDA, Food and Drug Administration; TGA, Therapeutic Goods Administration.
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cited in the other two frameworks at all. They also used “product
deviation” exclusively and used “clinical investigation” and “clin-
ical trial” interchangeably.
DISCUSSION
Biologic drugs must be developed and manufactured through
disciplined and specific mechanisms [3]. This is the case even
when full compliance with traditional concepts of pharmaceuti-
cal manufacturing practice is sometimes not possible (although
strived for), particularly for life-saving therapies and newmodal-
ities in investigational drug development [13]. These systems
incorporate considerations of risk-benefit ratios and include
mechanisms for the transparent and accountable release of
products [17].
Conditions of product requirements and release are estab-
lished and outlined in a spectrum of documents from the high-
tier regulatory documents down to the procedural documents.
Hence, the documents outlining the highest level of regulatory
requirements in three mature regulatory frameworks were ana-
lyzed by a documentary analysis method in order to establish
concomitance between different regional regulations applicable
to biologic drugs as a source of a specialized knowledge in regu-
latory science.
The commissioner of the FDA stated recently “that a failure
to invest ‘adequately’ in regulatory science has been one of the
reasons why fewer new drugs have been making it to the mar-
ket” [38]. In October 2010 the FDA promised to bring its “regu-
latory science” into the 21st century [39] and in August 2011
issued its strategic plan for regulatory science [40], called Ad-
vancing Regulatory Science in FDA [19]. The Common Fund’s
Regulatory Science program was initiated in the second half of
2010 as a partnership between the U.S. National Institutes of
Health (NIH) and the FDA [41].
At the same time, the EMA stated on its website that “the
European Medicines Agency is a key leader in the development
and application of regulatory science” [42] and referred to the
conference hosted by the Agency in December 2010, which re-
sulted in the report “Regulatory science: Are regulators leaders
or followers?” [43].
The origin of the term “regulatory science” is unknown; it is
believed that it was created in the 1970swhen the newly formed
U.S. Environmental Protection Agency was required to make de-
cisions based on incomplete and sometimes nonexistent scien-
tific information [44]. Although there is still some debate as to
whether it is necessary to use this new terminology “as science is
science regardless how it is applied” [44], the FDA currently de-
fines regulatory science as “the science of developing new tools,
standards, and approaches to assess safety, efficacy, quality, and
performance of all (FDA) regulated products” [45]. There is an
inevitable need to capture regulatory knowledge and expertise
required for the development of future regulatory policies to
enable safe application of new biologic drugs [46].
This study revealed numerous differences between the reg-
ulatory frameworks high-tier documents and the terminology
they employ. For instance, “marketing authorisation” was exclu-
sively used by the EMA regulatory framework, as was the phrase
“medicinal products.” Neither of these was mentioned at all in
the FDA and the TGA frameworks’ documents. “Class” and “clas-
sification of” were not mentioned at all in the FDA documents,
whereas the same phrases were usedminimally in the EMA doc-
uments (7 occurrences) but more frequently in the TGA docu-
ments (54 occurrences).
Whereas the most frequent word used in the EMA docu-
ments was “product(s),” along with “medicinal,” the term
“drug(s)” was consistently mentioned within all FDA documents
(84, 34, and 36 times) but seldom mentioned in the other two
frameworks (a total of 5 occasions). The TGA documents fea-
tured “biologic(s)/biological(s)” most consistently, whereas
“cell(s)” was most used in a document from the FDA framework
(78 occurrences in FDA DOC3) and the TGA framework (100 oc-
currences in TGA DOC1).
“Quality, safety and efficacy” was a phrase barely used in the
EMAand the TGAdocuments, and itwas not present in any of the
FDA documents. This also applied to the phrases “quality of” and
“manufacturing quality.”
This paper has described the processes that were used in the
research while developing a method of manual documentary
analysis for high-tier regulatory documents. Although the data
were studied out of context and the selectiveness of the data or
representativeness of the sample can be questioned, this ap-
proach to documentary analysis is particularly useful when the
researcher is faced with the vast amount of complex documents
with no common format, scope, or terminology.
Similar studies, aimed at analyzing or comparing regulatory
documents, have been performed in the pharmaceutical and
other industries (i.e., aviation and education) [47–50]. Irrespec-
tive of the area (industry) and a specific methodology (manual or
automated documentary analysis) used in each study, they have
added benefit to their respective areas. The purpose of these
studies was to provide a procedure for assessing connections
between the current regulations and incorporation of new re-
quirements [47], to increase understanding and knowledge
about the trends in success of regulatory submissions [48], or to
compare the regulatory versus the educational value of docu-
ments (i.e., guidances for undergraduate education for medical
practitioners) [49]. Someof the research looked into establishing
a clear definition of requirements or identifying inconsistencies
between those definitions [50].
In the process of choosing the documents for the study, an
ontological position was adopted that suggested that written
words, texts, and documents are meaningful constituents of the
process in the way in which they are changed and used [18]. In
addition, an epistemological position was adopted that sug-
gested that texts, documents, and written material can provide
or count toward evidence of these ontological properties. The
benefits of studies aimed at analyzing or comparing regulatory
documents have been already recognized in the health care in-
dustry [47], the pharmaceutical industry [48, 50], and aviation
and education fields [49], and qualitative documentary review
and analysis demonstrated its benefits to a number of other sec-
tors, such as political science [51]; environmental health re-
search [52]; ethics [53]; and the World Health Organization’s
health, economics, and policy-making research [54]. We have
observed that themain tasks in documentary analysis are a thor-
ough understanding of the analyzed documents, familiarity with
relevant terminological differences, and robust quality assur-
ance of the methodology [55–57].
The main advantages for the use of existing documents in a
research study are that the data are usually easy to access, it
takes a relatively short period of time to collect the data, and to
some extent it provides a relatively inexpensive form of data
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collection [35]. In addition, the documents are unbiased by the
data collection process (i.e., nonreactivity) andmay be useful for
hypothesis and problem formulation. Nonreactivity is one of the
main documentary analysis methodological strengths—“the
data selection method itself generally does not change the data
being collected” [36]. The stability of a measure refers to the
extent to which the same results are obtained on repeated ad-
ministrations of the instrument and it focuses on the instru-
ment’s susceptibility to “extraneous factors from one adminis-
tration to the next” [57]. We considered it appropriate to rely on
the “stability” of the documents since a retest measurement
facility was possible due to the nature of high-tier documents
available to the public and researchers. Reliability refers to the
accuracy of the research methods and techniques [58, 59]. The
process of reading, understanding, selecting, and comparing
documents added a further dimension of construction as well as
reflexivity—“textual analysis involves the mediation between
the frames of reference of the researcher and those who pro-
duced the text . . . the researcher’s own frame of reference be-
comes the springboard from which the circle is entered, and so
the circles reaches back to encompass the dialogue between the
researcher and the text” [60]. Careful consideration of the valid-
ity of data generation requires a precise application of the logic
used previously in determining methodological approaches—
the chosen methodology has to be more valid than other meth-
odological approaches [20]. To some extent there is a blurring of
the distinction between validity and reliability. The main ques-
tion posed here was how well the analyzed documents repre-
sented the concepts of the research or the hypothesis in an ac-
curate, authentic, and relevant manner [37]. Since the issue of
similarities and differences between the regulatory approaches
was examined, it appears appropriate to use high-tier regulatory
documents that establish the hallmark of these frameworks. It
would be difficult to justify the use of any other documentary
sources for this type of the research since the other documents
(i.e., lower-tier procedural texts or guidelines) are either overly
specialized in their aim or scope or not considered as mandatory
for every product.
Generally, qualitative research cannot entirely rely on stan-
dardized procedures to deal with concepts such as bias and re-
producibility [58]. In this process, reproducibility is often re-
placed with transparency or an audit trail (a record of the
researcher’s design decision) about gaining access, collecting
and analyzing the data, or the actual research design [59]. Man-
ual analysis with its quantified data (i.e., frequencies of terms
and phrases) along with the software analysis in Part II of this
study [11] (i.e., identifying concepts and themes) can be re-
peated accurately on many occasions and with no operator de-
pendence. The only variable potentially influencing the repro-
ducibility of the study relies upon selection of the documents to
be analyzed. Construct validity concerns the degree to which
results of documentary analysis documents reflect the underly-
ing theoretical concepts or exposure pointers. This would be
“the extent towhich the theoretical concepts have been success-
fully operationalised” and “ the process of translating research
concepts into measurable phenomena” [35]. Whereas the man-
ual documentary analysis obtained in Part I (this paper) provides
semantics analysis, the software-based analysis in Part II [11] is
expected to assist in conveying contexts and relations between
the concepts supported by visual representation [60]. Validity of
the construct was established by the assumption that differ-
ences in the regulatory frameworks were dictated by different
historical and cultural backgrounds, regional dynamics, and var-
ious complexities of the biologic drugs’ development. Neverthe-
less, some shared concerns were considered an underpinning
factor for similarities among the regulatory frameworks, such as
public and individual safety and a uniform scientific knowledge.
Validity of interpretation is another way to think about the valid-
ity of the research. It is concerned with the data analysis validity
and the interpretation on which it is based; it is contingent upon
the end result, including how that interpretation was reached
[20]. The validity of interpretation was established in two ways:
first, by making the process of reaching our interpretations as
transparent as possible, and second, by following the same logic
in making methodological choices and identifying the sources to
be used (i.e., analyzed documents). Furthermore, the intent of
the research was to provide some level of generalization, since it
examined a broad set of regulations in the developed world (i.e.,
Europe, the U.S., and Australia). Generalization is sometimes
perceived in two distinct ways: empirical (i.e., one empirical pop-
ulation is representative of a wider population) and theoretical
[20]. Theoretical generalization is often seen asmore productive
as it encompasses a range of strategies based on different logics,
some of which are more “theoretical” than others (i.e., attaining
a wider perspective) [20]. The aim in the theoretical generaliza-
tion of this research was to demonstrate that high-tier regula-
tory documents are a central representation of the regulatory
frameworks from which they are drawn. The comparison aimed
to contribute more to the generalization than a simple state-
ment of similarity or discrepancy. It was also designed to pose
questions for future regulatory studies. What questions do all
regulatory agencies want answered?What are the specific areas
they emphasize? In what specific areas do they converge/di-
verge, and how can the lessons learned from a conventional
pharmaceutical model(s) be applied to biopharmaceutical(s) de-
velopment? It is well known that the biggest risk in drug devel-
opment is failure to convince a regulator that a therapeutic prod-
uctmeets the requirements for the next stage of development or
marketing approval. It is also becoming clear that regulatory ed-
ucation and precedence information analysis [61], along with
thorough knowledge of regulatory framework(s) and their focus,
are the most acceptable development strategies for a smarter
product development pathway. Not only do they require fewer
clinical and nonclinical trials while reducing time and related cost
[61], but they also potentially bring development of a biologic
drug closer to market approval stage in different regions [62].
CONCLUSION
This research draws attention to the importance of understand-
ing the complexity of a global regulatory environment applicable
to biologic drugs, including stem cells or their progeny. It dem-
onstrates considerable differences in the regulatory approach to
biologic drugs’ development and application, particularly with
respect to terminology and definitions used in regional regula-
tory frameworks. The EMA documents were mostly concerned
with “marketing authorisation(s)” but occasionally mentioned
“quality, safety and efficacy”; the FDA documents discussed
“drug(s)” or “investigational drug(s)” that were not cited in the
other two frameworks at all, used “product deviation” exclu-
sively, and used “clinical investigation” and “clinical trial” inter-
changeably. Whereas the most frequent word used in the EMA
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documents was “product(s),” along with “medicinal,” the term
“drug(s)” was consistently mentioned within all FDA documents
but seldom mentioned in the other two frameworks. The TGA
documents featured “biologic/biological(s)” most consistently,
whereas “cell(s)” was most used in a document from the FDA
framework and the TGA framework.
Nevertheless, this study identifies some conjoint aspects
(i.e., the focus on the “product” whether it is referred to as “me-
dicinal product,” “drug/biologic,” or “biological,” so the terms
“drug(s),” “cell(s),” and “biologic/biological(s)” were to some ex-
tent used across the entire spectrum of analyzed documents)
and common principles (i.e., the TGA documents refer often to
“manufacturing” whereas the documents of the other two
frameworks referred to it to a lesser extent, and all documents
use the term “human” in a comparable manner).
Although the data were studied out of context and the selec-
tiveness of the data or representativeness of the sample can be
questioned, this approach to documentary analysis is particu-
larly useful when the researcher is facedwith the vast amount of
complex documents with no common format, scope and termi-
nology. Hence, further documentary analysis has been gener-
ated in Part II of this study [11].
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